The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 26, 2016

Filed:

Mar. 14, 2013
Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Hans Guido Wendel, New York, NY (US);

Elisa Oricchio, New York, NY (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/495 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2006.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/635 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/404 (2013.01); A61K 31/495 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.


Find Patent Forward Citations

Loading…